Takeda Pharmaceutical (TAK) Capital Expenditures Growth (3y) (2021 - 2026)
Takeda Pharmaceutical (TAK) Capital Expenditures Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.93 Bn | 32.19 Bn | 1.97 Bn | 6.52% |
| 3 | Zoetis | 32.55 Bn | 30.61 Bn | 1.62 Bn | 232.22% |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn | 1.64% |
| 5 | United Therapeutics | 23.08 Bn | 20.92 Bn | 648.10 Mn | 75.58% |
| 6 | RedHill Biopharma | 22.43 Bn | 22.43 Bn | - | - |
| 7 | Viatris | 20.27 Bn | 18.47 Bn | 1.16 Bn | -5.84% |
| 8 | Neurocrine Biosciences | 17.73 Bn | 16.41 Bn | 800.70 Mn | 32.64% |
| 9 | Elanco Animal Health | 12.63 Bn | 12.20 Bn | 785.00 Mn | 28.56% |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | 279.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.64% |
| Dec 31, 2025 | -4.53% |
| Sep 30, 2025 | -8.65% |
| Jun 30, 2025 | -0.55% |
| Mar 31, 2025 | 8.41% |
| Dec 31, 2024 | -7.59% |
| Sep 30, 2024 | -5.88% |
| Jun 30, 2024 | -10.62% |
| Mar 31, 2024 | 5.51% |
| Dec 31, 2023 | -10.66% |
| Sep 30, 2023 | -0.59% |
| Jun 30, 2023 | -15.95% |
| Mar 31, 2023 | -2.33% |
| Sep 30, 2022 | 3.36% |
| Jun 30, 2022 | -6.25% |
| Mar 31, 2022 | 15.99% |
| Dec 31, 2021 | -27.14% |
| Sep 30, 2021 | -20.70% |
| Jun 30, 2021 | -14.87% |
| Mar 31, 2021 | 18.17% |